Pediatric acute-onset neuropsychiatric syndrome (PANS) is a clinically defined neuropsychiatric condition of childhood characterized by the abrupt, dramatic onset of obsessive-compulsive disorder or severely restricted food intake, accompanied by at least two concurrent neuropsychiatric symptoms such as anxiety, emotional lability or depression, irritability/aggression, behavioral regression, deterioration in school performance, sensory or motor abnormalities, and somatic signs including sleep disturbance or enuresis. PANS is defined by its clinical phenotype and time course rather than by a single trigger: it is proposed to reflect a post-infectious and/or immune-mediated neuroinflammatory process affecting the basal ganglia, of which streptococcal infection (PANDAS) is one well-studied precipitant. The concept was introduced in 2012 to broaden the earlier PANDAS criteria beyond group A streptococcus to encompass other infectious, immune, and metabolic triggers. It remains a clinically defined and debated entity without a validated confirmatory biomarker.
Ask a research question about Pediatric Acute-onset Neuropsychiatric Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Pediatric Acute-onset Neuropsychiatric Syndrome:
name: Pediatric Acute-onset Neuropsychiatric Syndrome
creation_date: "2026-07-25T00:00:00Z"
category: Autoimmune
description: >-
Pediatric acute-onset neuropsychiatric syndrome (PANS) is a clinically defined
neuropsychiatric condition of childhood characterized by the abrupt, dramatic
onset of obsessive-compulsive disorder or severely restricted food intake,
accompanied by at least two concurrent neuropsychiatric symptoms such as
anxiety, emotional lability or depression, irritability/aggression, behavioral
regression, deterioration in school performance, sensory or motor
abnormalities, and somatic signs including sleep disturbance or enuresis. PANS
is defined by its clinical phenotype and time course rather than by a single
trigger: it is proposed to reflect a post-infectious and/or immune-mediated
neuroinflammatory process affecting the basal ganglia, of which streptococcal
infection (PANDAS) is one well-studied precipitant. The concept was introduced
in 2012 to broaden the earlier PANDAS criteria beyond group A streptococcus to
encompass other infectious, immune, and metabolic triggers. It remains a
clinically defined and debated entity without a validated confirmatory
biomarker.
disease_term:
preferred_term: pediatric acute-onset neuropsychiatric syndrome
term:
id: MONDO:1060178
label: pediatric acute-onset neuropsychiatric syndrome
parents:
- Autoimmune Disease
- Mental Health Disorder
pathophysiology:
- name: Post-infectious / immune-mediated basal ganglia neuroinflammation
description: >-
PANS is hypothesized to arise when an infectious or immune trigger provokes a
dysregulated immune response that, via molecular mimicry and/or
neuroinflammation, targets the basal ganglia, disrupting
cortico-striato-thalamo-cortical circuits and producing acute-onset
obsessive-compulsive and neuropsychiatric symptoms. Unlike PANDAS, PANS does
not require a demonstrated streptococcal trigger and may follow other
infections (e.g., Mycoplasma, viral) or non-infectious immune activation.
biological_scale: TISSUE
downstream:
- target: Acute-onset obsessive-compulsive behavior
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
description: >-
Basal ganglia dysfunction is modeled upstream of the abrupt
obsessive-compulsive presentation, one of the two cardinal features.
- target: Restricted food intake
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
description: >-
The alternative cardinal presentation, modeled from the same basal ganglia
process.
- target: Anxiety
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
description: >-
One of the concurrent neuropsychiatric manifestations the diagnostic
criteria require alongside a cardinal feature.
- target: Emotional lability
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
description: >-
A second concurrent neuropsychiatric manifestation from the same process.
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Symptom onset is often temporally associated with infections, suggesting
an underlying autoimmune/autoinflammatory etiology, although direct
evidence is often lacking.
explanation: >-
Supports the post-infectious/immune-mediated framing while noting that
direct proof of autoimmunity is frequently lacking.
- name: Broadened diagnostic construct beyond streptococcus
notes: >-
Deliberately carries no `biological_scale` and no `downstream` edges. This
node records how the diagnostic category was drawn, not a process or state
in a patient, so no scale applies to it and it has nothing mechanistic to be
upstream of. It is kept in `pathophysiology` rather than moved to
`description` or `discussions` because the trigger-agnostic boundary is what
separates this entry from the PANDAS one, and it carries its own cited
evidence; a reviewer who would prefer nosology out of the pathograph should
read this as the decision rather than an oversight.
description: >-
PANS was defined to capture children with an abrupt-onset PANDAS-like
presentation in whom a streptococcal trigger cannot be established,
reframing the condition around its acute neuropsychiatric phenotype and
time course rather than a specific pathogen. PANDAS is the subset in which
group A streptococcal infection is the identified precipitant.
evidence:
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Unlike PANDAS, PANS is not strictly linked to group A streptococcal
infections but can be triggered by various infectious or environmental
factors.
explanation: >-
The 2024 Delphi consensus states that PANS, unlike PANDAS, is not
restricted to streptococcal triggers, supporting the broadened construct.
- name: Candidate susceptibility genes converging on immune and synaptic pathways
biological_scale: MOLECULAR
description: >-
PANS has no established causal gene. A 2022 exome/genome sequencing study of
a US cohort (386 cases) plus 10 severe European cases identified de novo or
ultra-rare candidate variants in 11 genes (PPM1D, SGCE, PLCG2, NLRC4,
CACNA1B, SHANK3, CHEK2, GRIN2A, RAG1, GABRG2, SYNGAP1) in 21 cases,
partitioning into peripheral-immune/microglial and neuronal/synaptic
functional categories. These are hypothesis-generating susceptibility
candidates rather than diagnostic markers, and many cases arose on a
pre-existing neurodevelopmental disorder.
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
genetic variation in PANS candidate genes may function by disrupting
peripheral and central immune functions, neurotransmission, and/or the
blood-CSF/brain barriers following stressors such as infection
explanation: >-
Supports the candidate-gene convergence on immune and synaptic/barrier
functions as a susceptibility mechanism.
phenotypes:
- name: Acute-onset obsessive-compulsive behavior
description: >-
Abrupt, dramatic onset of obsessions and compulsions is one of the two
cardinal presenting features of PANS.
phenotype_term:
preferred_term: Compulsive behaviors
term:
id: HP:0000722
label: Compulsive behaviors
temporality: ACUTE
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Abrupt onset of severe neuropsychiatric symptoms including obsessive-compulsive disorder, tics, anxiety, mood swings, irritability, and restricted eating is described in children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS).
explanation: >-
The full source sentence, which names both the abruptness and the
obsessive-compulsive disorder this phenotype asserts. The earlier quote
began mid-sentence and dropped the words "obsessive-compulsive disorder".
- name: Restricted food intake
description: >-
Severely restricted food intake is an alternative cardinal presenting
feature of PANS, sometimes driven by contamination fears, sensory changes,
or fear of choking rather than body-image concerns.
phenotype_term:
preferred_term: Restrictive eating
term:
id: HP:0020302
label: Restrictive eating
temporality: ACUTE
notes: >-
Bound to `HP:0020302` Restrictive eating rather than `HP:0002039` Anorexia.
HPO defines `HP:0002039` as loss of appetite, which is the opposite of what
this entry describes: the restriction here is intentional and driven by
contamination or choking fears. `HP:0020302`'s own definition draws that
distinction explicitly ("the intentional restriction of eating, not merely a
loss of appetite"), and `Avoidant_Restrictive_Food_Intake_Disorder.yaml`
already uses it in the analogous context.
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Abrupt onset of severe neuropsychiatric symptoms including obsessive-compulsive disorder, tics, anxiety, mood swings, irritability, and restricted eating is described in children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS).
explanation: >-
Names restricted eating among the abrupt-onset symptoms described in PANS.
- name: Anxiety
description: >-
Acute, often severe anxiety (including separation anxiety) is a common
concurrent neuropsychiatric symptom.
phenotype_term:
preferred_term: Anxiety
term:
id: HP:0000739
label: Anxiety
temporality: ACUTE
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Abrupt onset of severe neuropsychiatric symptoms including obsessive-compulsive disorder, tics, anxiety, mood swings, irritability, and restricted eating is described in children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS).
explanation: >-
Names anxiety among the abrupt-onset symptom cluster described in PANS.
- name: Emotional lability
description: >-
Rapid mood swings and emotional lability or depression are frequent
concurrent symptoms.
phenotype_term:
preferred_term: Emotional lability
term:
id: HP:0000712
label: Emotional lability
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Abrupt onset of severe neuropsychiatric symptoms including obsessive-compulsive disorder, tics, anxiety, mood swings, irritability, and restricted eating is described in children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS).
explanation: >-
The source names mood swings, which is what this phenotype records.
- name: Enuresis
description: >-
Urinary frequency or new-onset enuresis is among the somatic signs
supporting the diagnosis.
phenotype_term:
preferred_term: Enuresis
term:
id: HP:0000805
label: Enuresis
notes: >-
Deliberately not wired to the basal ganglia node. The consensus criteria
list urinary frequency and new-onset enuresis among the somatic signs that
support a PANS diagnosis, but no source cited here proposes a route from
basal ganglia neuroinflammation to it, and inventing that edge would assert
a mechanism nothing here supports.
genetic:
- name: PPM1D
gene_term:
preferred_term: PPM1D
term:
id: hgnc:9277
label: PPM1D
relationship_type: SUSCEPTIBILITY
variant_origin: GERMLINE
presence: >-
One of eleven genes in which de novo or ultra-rare candidate variants were
found in 21 cases across the study's combined exome and genome sequencing
cohorts, assigned by the authors to the
peripheral immune / microglial category.
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Candidate mutations were found in 11 genes (PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1) in 21 cases, which included two or more unrelated subjects with ultra-rare variants in four genes.
explanation: >-
The candidate-gene list this record and its ten siblings are drawn from.
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Consequently, we conducted whole exome sequencing (WES) on a U.S. cohort of 386 cases, and whole genome sequencing (WGS) on ten cases from the European Union who were selected because of severe PANS.
explanation: >-
The cohorts the 21 variant-carrying cases are drawn from, so the
denominator behind this candidate list is quotable rather than derived.
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
These genes converge into two broad functional categories. One regulates peripheral immune responses and microglia (PPM1D, CHK2, NLRC4, RAG1, PLCG2). The other is expressed primarily at neuronal synapses (SHANK3, SYNGAP1, GRIN2A, GABRG2, CACNA1B, SGCE).
explanation: >-
The two functional categories the eleven genes partition into.
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In fact, 12/21 cases developed PANS superimposed on a preexisting neurodevelopmental disorder.
explanation: >-
Records that most variant-carrying cases had a pre-existing
neurodevelopmental disorder, which is why these are typed
SUSCEPTIBILITY rather than CAUSATIVE.
- name: SGCE
gene_term:
preferred_term: SGCE
term:
id: hgnc:10808
label: SGCE
relationship_type: SUSCEPTIBILITY
variant_origin: GERMLINE
presence: >-
One of eleven genes in which de novo or ultra-rare candidate variants were
found in 21 cases across the study's combined exome and genome sequencing
cohorts, assigned by the authors to the
neuronal synaptic category.
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Candidate mutations were found in 11 genes (PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1) in 21 cases, which included two or more unrelated subjects with ultra-rare variants in four genes.
explanation: >-
Names this gene in the candidate list.
- name: PLCG2
gene_term:
preferred_term: PLCG2
term:
id: hgnc:9066
label: PLCG2
relationship_type: SUSCEPTIBILITY
variant_origin: GERMLINE
presence: >-
One of eleven genes in which de novo or ultra-rare candidate variants were
found in 21 cases across the study's combined exome and genome sequencing
cohorts, assigned by the authors to the
peripheral immune / microglial category.
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Candidate mutations were found in 11 genes (PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1) in 21 cases, which included two or more unrelated subjects with ultra-rare variants in four genes.
explanation: >-
Names this gene in the candidate list.
- name: NLRC4
gene_term:
preferred_term: NLRC4
term:
id: hgnc:16412
label: NLRC4
relationship_type: SUSCEPTIBILITY
variant_origin: GERMLINE
presence: >-
One of eleven genes in which de novo or ultra-rare candidate variants were
found in 21 cases across the study's combined exome and genome sequencing
cohorts, assigned by the authors to the
peripheral immune / microglial category.
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Candidate mutations were found in 11 genes (PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1) in 21 cases, which included two or more unrelated subjects with ultra-rare variants in four genes.
explanation: >-
Names this gene in the candidate list.
- name: CACNA1B
gene_term:
preferred_term: CACNA1B
term:
id: hgnc:1389
label: CACNA1B
relationship_type: SUSCEPTIBILITY
variant_origin: GERMLINE
presence: >-
One of eleven genes in which de novo or ultra-rare candidate variants were
found in 21 cases across the study's combined exome and genome sequencing
cohorts, assigned by the authors to the
neuronal synaptic category.
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Candidate mutations were found in 11 genes (PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1) in 21 cases, which included two or more unrelated subjects with ultra-rare variants in four genes.
explanation: >-
Names this gene in the candidate list.
- name: SHANK3
gene_term:
preferred_term: SHANK3
term:
id: hgnc:14294
label: SHANK3
relationship_type: SUSCEPTIBILITY
variant_origin: GERMLINE
presence: >-
One of eleven genes in which de novo or ultra-rare candidate variants were
found in 21 cases across the study's combined exome and genome sequencing
cohorts, assigned by the authors to the
neuronal synaptic category.
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Candidate mutations were found in 11 genes (PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1) in 21 cases, which included two or more unrelated subjects with ultra-rare variants in four genes.
explanation: >-
Names this gene in the candidate list.
- name: CHEK2
gene_term:
preferred_term: CHEK2
term:
id: hgnc:16627
label: CHEK2
relationship_type: SUSCEPTIBILITY
variant_origin: GERMLINE
presence: >-
One of eleven genes in which de novo or ultra-rare candidate variants were
found in 21 cases across the study's combined exome and genome sequencing
cohorts, assigned by the authors to the
peripheral immune / microglial category.
notes: >-
The source sentence spells this gene CHK2, which is not an HGNC symbol; the
binding is to `hgnc:16627` CHEK2, the gene that name refers to. Quoted as
written rather than corrected inside the snippet.
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Candidate mutations were found in 11 genes (PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1) in 21 cases, which included two or more unrelated subjects with ultra-rare variants in four genes.
explanation: >-
Names this gene in the candidate list.
- name: GRIN2A
gene_term:
preferred_term: GRIN2A
term:
id: hgnc:4585
label: GRIN2A
relationship_type: SUSCEPTIBILITY
variant_origin: GERMLINE
presence: >-
One of eleven genes in which de novo or ultra-rare candidate variants were
found in 21 cases across the study's combined exome and genome sequencing
cohorts, assigned by the authors to the
neuronal synaptic category.
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Candidate mutations were found in 11 genes (PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1) in 21 cases, which included two or more unrelated subjects with ultra-rare variants in four genes.
explanation: >-
Names this gene in the candidate list.
- name: RAG1
gene_term:
preferred_term: RAG1
term:
id: hgnc:9831
label: RAG1
relationship_type: SUSCEPTIBILITY
variant_origin: GERMLINE
presence: >-
One of eleven genes in which de novo or ultra-rare candidate variants were
found in 21 cases across the study's combined exome and genome sequencing
cohorts, assigned by the authors to the
peripheral immune / microglial category.
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Candidate mutations were found in 11 genes (PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1) in 21 cases, which included two or more unrelated subjects with ultra-rare variants in four genes.
explanation: >-
Names this gene in the candidate list.
- name: GABRG2
gene_term:
preferred_term: GABRG2
term:
id: hgnc:4087
label: GABRG2
relationship_type: SUSCEPTIBILITY
variant_origin: GERMLINE
presence: >-
One of eleven genes in which de novo or ultra-rare candidate variants were
found in 21 cases across the study's combined exome and genome sequencing
cohorts, assigned by the authors to the
neuronal synaptic category.
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Candidate mutations were found in 11 genes (PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1) in 21 cases, which included two or more unrelated subjects with ultra-rare variants in four genes.
explanation: >-
Names this gene in the candidate list.
- name: SYNGAP1
gene_term:
preferred_term: SYNGAP1
term:
id: hgnc:11497
label: SYNGAP1
relationship_type: SUSCEPTIBILITY
variant_origin: GERMLINE
presence: >-
One of eleven genes in which de novo or ultra-rare candidate variants were
found in 21 cases across the study's combined exome and genome sequencing
cohorts, assigned by the authors to the
neuronal synaptic category.
evidence:
- reference: PMID:35773312
reference_title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Candidate mutations were found in 11 genes (PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHK2, GRIN2A, RAG1, GABRG2, and SYNGAP1) in 21 cases, which included two or more unrelated subjects with ultra-rare variants in four genes.
explanation: >-
Names this gene in the candidate list.
notes: >-
PANS has no established causal gene and none of these eleven is a diagnostic
marker. They are typed `SUSCEPTIBILITY` because that is what the source
claims for them: hypothesis-generating candidates from a single
exome/genome-sequencing study, found in 21 cases, more than half of whom
already carried a neurodevelopmental diagnosis. SHANK3, GRIN2A and
SYNGAP1 have their own dismech entries; their appearance here is not a claim
that PANS is those disorders.
diagnosis:
- name: Clinical diagnostic criteria
presence: >-
PANS is a clinical diagnosis requiring abrupt, dramatic onset of OCD or
severely restricted food intake plus at least two concurrent
neuropsychiatric symptoms, with symptoms not better explained by a known
neurologic or medical disorder.
diagnosis_term:
preferred_term: clinical diagnosis
term:
id: NCIT:C124351
label: Clinical Evaluation
evidence:
- reference: PMID:25325534
reference_title: "Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Presented here is a consensus statement proposing recommendations for the
diagnostic evaluation of youth presenting with PANS.
explanation: >-
The 2013 PANS Consensus Conference statement provides the clinical
diagnostic-evaluation framework for PANS.
treatments:
- name: Anti-infective Treatment of the Identified Trigger
description: >-
Where an infectious trigger is identified, treating it is the first
therapeutic priority. For group A streptococcus the consensus names an
initial 6-10 day course of amoxicillin, penicillin, or a cephalosporin where
allergy is documented.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Antibiotic Therapy
term:
id: NCIT:C15620
label: Antibiotic Therapy
therapeutic_agent:
- preferred_term: amoxicillin
term:
id: CHEBI:2676
label: amoxicillin
evidence:
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Concerning GAS infections, an initial course with an effective treatment on GAS (amoxicillin, penicillin, cephalosporin in case of documented allergic reactions) for 6-10 days is recommended
explanation: >-
The consensus antibiotic regimen for the streptococcal trigger, which is
the agent this record binds.
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Neuropsychiatric symptoms (especially the obsessive-compulsive ones) improve rapidly with an effective antibiotic treatment in eradicating the infection.
explanation: >-
States the claimed neuropsychiatric effect of eradicating the infection.
notes: >-
The quote names amoxicillin, penicillin and cephalosporins; only amoxicillin
is bound as a `therapeutic_agent` because the slot takes specific agents and
"cephalosporin" is a class the consensus offers as an allergy alternative
rather than a named drug. The consensus is explicit that the antibiotic
evidence base is small and not conclusive.
- name: Corticosteroid and Immunomodulatory Therapy
description: >-
Immunomodulatory treatment is reserved for severe or selected cases. The
consensus reports good responses to corticosteroids in some
virus-triggered presentations while stating that the literature is thin and
that routine use cannot be recommended.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Systemic Corticosteroid Therapy
term:
id: NCIT:C122080
label: Systemic Corticosteroid Therapy
therapeutic_agent:
- preferred_term: corticosteroid
term:
id: CHEBI:50858
label: corticosteroid
evidence:
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
In the case of PANS triggered by viral infections, some patients showed a good response to antivirals and to corticosteroid therapy, but there is little evidence in literature.
explanation: >-
The consensus statement on corticosteroids, including its own caveat that
the supporting literature is limited.
- name: Intravenous Immunoglobulin
description: >-
IVIG is positioned as a later-line immunomodulatory option, restricted to
severely affected children in whom steroid therapy has failed or is not
feasible.
therapeutic_modality: OTHER
treatment_term:
preferred_term: Intravenous Immunoglobulin Therapy
term:
id: NCIT:C121331
label: Intravenous Immunoglobulin Therapy
evidence:
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Their indications for the use of IVIG in PANS patients state that this treatment should only be implied in children who are severely affected and if there is no effect by steroid therapy or if this therapy is not feasible.
explanation: >-
States the restriction of IVIG to severely affected, steroid-refractory
children, which is what this record's description asserts.
notes: >-
`therapeutic_modality: OTHER` because polyclonal pooled immunoglobulin is
none of the enum's named platforms - it is not a monoclonal antibody and not
protein replacement for a missing gene product.
- name: Cognitive Behavioral Therapy and SSRI
description: >-
Psychotherapeutic management, principally cognitive-behavioral therapy with
low-dose SSRIs for the obsessive-compulsive symptoms, is one of the three
arms of PANS management alongside anti-infective and immunomodulatory
treatment.
therapeutic_modality: BEHAVIORAL
treatment_term:
preferred_term: Cognitive Behavior Therapy
term:
id: NCIT:C64345
label: Cognitive Behavior Therapy
evidence:
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
CBT and other forms of psychotherapy have an important role especially in reducing the obsessive-compulsive neuro-psychiatric symptoms in patients with PANS or PANDAS.
explanation: >-
States the role of CBT in reducing the obsessive-compulsive symptoms.
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
the psychiatric symptoms in these patients are usually treated with CBT and that the OCD generally respond well to SSRI at small doses
explanation: >-
The pharmacological half of this record, naming low-dose SSRIs for the OCD
symptoms.
- reference: PMID:39512340
reference_title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The PANS and PANDAS treatment is based on antibiotics, psychotherapeutic treatment (through drugs and/or cognitive-behavioral therapy) and – on immunomodulatory therapy in severe selected cases.
explanation: >-
Places psychotherapeutic treatment as one of the three management arms,
which is how this record is scoped.
notes: >-
Bound to the behavioural term because that is the modality the consensus
sentence leads with; the SSRI component is carried by its own evidence item
rather than a second `therapeutic_agent`, since the source names the drug
class and no specific agent.
differential_diagnoses:
- name: Sydenham chorea
description: >-
The post-streptococcal movement disorder with which PANDAS, and therefore
the streptococcal end of the PANS spectrum, shares an anti-basal-ganglia
antibody mechanism.
distinguishing_features:
- >-
Sydenham chorea is defined by chorea as its motor presentation and is a
major criterion of acute rheumatic fever; PANS is defined by abrupt
obsessive-compulsive symptoms or restricted eating without requiring chorea
or rheumatic fever.
- name: Tourette Syndrome
description: >-
A primary chronic tic disorder of childhood.
distinguishing_features:
- >-
Tourette syndrome has a gradual onset and a chronic waxing-and-waning course
from early childhood; PANS requires an abrupt, dramatic onset and is not a
tic disorder by definition.
- name: Obsessive-Compulsive Disorder
description: >-
Primary childhood obsessive-compulsive disorder without an acute onset or an
identified infectious or immune trigger.
distinguishing_features:
- >-
Primary OCD typically has an insidious onset and lacks the concurrent
neuropsychiatric and somatic signs that the PANS criteria require alongside
the obsessive-compulsive presentation.
discussions:
- discussion_id: pans_no_confirmatory_biomarker
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- diagnosis#Clinical diagnostic criteria
prompt: >-
Is there any laboratory or imaging measurement that confirms PANS, rather
than only excluding alternatives?
rationale: >-
PANS is defined entirely by clinical phenotype and time course. The entry's
own pathophysiology nodes propose a post-infectious immune-mediated basal
ganglia process, but the sequencing study cited here says in as many words
that direct evidence of autoimmunity is often lacking, and no cited source
offers a confirmatory test. Until one exists, every mechanistic node in this
entry rests on a diagnosis that cannot be independently verified, which
bounds what the entry can claim.
evidence:
- reference: PMID:37251418
reference_title: "Pediatric Acute-Onset Neuropsychiatric Syndrome: Current Perspectives"
supports: SUPPORT
evidence_source: OTHER
quote_role: REVIEW_SYNTHESIS
snippet: >-
Although several biomarkers (particularly those related to the post-infectious and auto-immune mechanism response) are regularly used in PANS diagnostic process, more information is needed about their correlation with specific clinical features and with PANS symptoms severity.
explanation: >-
A review of the PANS biomarker literature concluding that the markers in
diagnostic use are not yet correlated with clinical features or severity,
which is the gap this discussion records.
- reference: PMID:30996598
reference_title: "PANDAS/PANS in childhood: Controversies and evidence"
supports: SUPPORT
evidence_source: OTHER
quote_role: REVIEW_SYNTHESIS
snippet: >-
Notably, however, to date, biological studies have failed to show children satisfying PANDAS/PANS criteria to have a clear immune basis.
explanation: >-
States that biological studies have not shown a clear immune basis in
children meeting the criteria, which is what leaves the mechanistic nodes
in this entry resting on a clinically defined diagnosis. Chosen over the
same paper's "definitive proof of the autoimmune hypothesis of PANDAS is
lacking" because that sentence is scoped to PANDAS while this gap is on
the PANS entry; this one is scoped to PANDAS/PANS criteria together.
notes: >-
Four things about this entry are deliberate.
First, **the restricted-eating phenotype is bound to `HP:0020302` Restrictive
eating, not `HP:0002039` Anorexia.** The reasoning is on the phenotype itself:
HPO defines Anorexia as loss of appetite, and this entry's own description says
the restriction is intentional and fear-driven.
Second, **eleven candidate genes are typed `SUSCEPTIBILITY`, not `CAUSATIVE`.**
They come from a single exome/genome study, were found in 21 of 396 cases, and
more than half of those cases already carried a neurodevelopmental diagnosis.
The source calls them candidates; so does this entry.
Third, **`Enuresis` is deliberately unwired** and says so in its own `notes`:
the consensus lists it as a supporting somatic sign, and nothing cited here
connects it to the basal ganglia process the other phenotypes hang off.
Fourth, **the "Broadened diagnostic construct beyond streptococcus" node is a
nosological statement kept inside `pathophysiology` on purpose**, with the
reasoning recorded on the node. It is the boundary that separates this entry
from the PANDAS one.
Two references were repaired rather than dropped in the review round. This
entry originally cited `DOI:10.2147/NDT.S362202` and `DOI:10.1093/pch/pxy145`,
both of which cache with `content_type: unavailable` and an empty body, so
nothing could ever have been quoted from either. Both resolve to PubMed
records with full text (`PMID:37251418` and `PMID:30996598`), and both are now
quoted as evidence on the knowledge-gap discussion above - which is the reason
to repair a reference rather than drop it.
references:
- reference: PMID:34778136
title: "Diagnostic Approach to Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections (PANDAS): A Narrative Review of Literature Data"
findings: []
- reference: PMID:39512340
title: "Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up"
findings: []
- reference: PMID:35773312
title: "Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (PANS) by exome and whole genome sequencing"
findings: []
- reference: PMID:25325534
title: "Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference."
findings: []
- reference: PMID:37251418
title: "Pediatric Acute-Onset Neuropsychiatric Syndrome: Current Perspectives"
findings: []
- reference: PMID:30996598
title: "PANDAS/PANS in childhood: Controversies and evidence"
findings: []
Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.
Create: PANS, with the PR #7458 review round folded in · 2026-09-20T23:52:54Z · View source
Creation of the PANS entry, plus the review round on PR #7458 answering all seven blocking items from the two CHANGES_REQUESTED reviews of 2026-08-01 and 2026-08-08. Written as one record because no history record was ever added for the original creation, which was blocking item 6. Original curation: Falcon deep-research-sourced, MONDO:1060178, NEC preflight against the confusable PANDAS acronym, every snippet an exact substring of a cached abstract. Item 1, the wrong phenotype term. The cardinal restricted-eating phenotype was bound to HP:0002039 Anorexia, which HPO defines as loss of appetite - the semantic opposite of what the entry's own description says, namely intentional restriction driven by contamination, sensory, or choking fears. Rebound to HP:0020302 Restrictive eating, whose definition draws that distinction explicitly, and which Avoidant_Restrictive_Food_Intake_Disorder.yaml already uses in the analogous context. The reasoning is recorded on the phenotype rather than only here. The same leaf in the grouping's membership criteria was corrected to match. Item 3, a snippet truncated past its own claim. The phenotype "Acute-onset obsessive-compulsive behavior" was supported by a quote starting mid-sentence at "tics, anxiety, mood swings..." which listed every symptom except the obsessive-compulsive disorder the phenotype asserts. Replaced with the full source sentence from PMID:35773312, which names both the abruptness and the OCD. This validated either way, which is why it needed a human read rather than a gate. Item 5, a dangling causal edge. The pathophysiology node's only downstream target, "Acute-onset obsessive-compulsive and neuropsychiatric symptoms", matched no node or phenotype name in the file and would have rendered as a phantom node. Replaced with four resolving edges to the phenotypes the node's own description names - the two cardinal features plus anxiety and emotional lability - each marked INDIRECT_UNKNOWN_INTERMEDIATES. Item 7, eleven candidate genes in prose with no genetic block. Added genetic: with all eleven (PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHEK2, GRIN2A, RAG1, GABRG2, SYNGAP1), typed relationship_type SUSCEPTIBILITY rather than CAUSATIVE because that is what the source claims: candidates from a single exome/genome study, found in 21 of 396 cases, with 12 of 21 developing PANS on a pre-existing neurodevelopmental disorder. That last figure is curated as its own evidence item so the typing is defensible from the entry rather than from this note. NLRC4 (hgnc:16412) and CACNA1B (hgnc:1389) were not in cache/hgnc/terms.csv and were resolved at rest.genenames.org. The source sentence spells CHEK2 as "CHK2", which is not an HGNC symbol; the binding is to hgnc:16627 CHEK2 and the gene record says so, since a reader of just list-gene-term-mismatches would otherwise see an unexplained symbol. Item 2, no treatments block. Added four records - anti-infective treatment of the identified trigger, systemic corticosteroid therapy, IVIG, and CBT with SSRIs - all sourced from the already-cached full text of the 2024 Delphi consensus PMID:39512340. That cache is content_type full_text_pdf and carries ligature corruption (the fi ligature) and broken intra-word spacing in places, so every snippet was extracted programmatically from the cache text rather than typed, and spans containing corruption were avoided. IVIG is therapeutic_modality OTHER because polyclonal pooled immunoglobulin matches none of the enum's named platforms. Suggestions taken: temporality ACUTE on the cardinal phenotypes; evidence added to the previously uncited Anxiety and Emotional lability phenotypes, raising phenotype evidence coverage from 1/5; NCIT:C15220 Diagnosis Assessment swapped for NCIT:C124351 Clinical Evaluation, which is used 146 times elsewhere in the KB and matches preferred_term "clinical diagnosis" better; differential_diagnoses added for Sydenham chorea, Tourette syndrome, and primary OCD; a KNOWLEDGE_GAP discussion recording the absence of any confirmatory biomarker, which bounds every mechanistic claim in the entry; biological_scale set where a scale applies. Suggestion declined, with the reason recorded on the node: the "Broadened diagnostic construct beyond streptococcus" node is a nosological statement and the reviewer offered to be overruled on whether it belongs in pathophysiology. It is kept there because the trigger-agnostic boundary is what separates this entry from the PANDAS one and it carries its own cited evidence, and the node's notes now say that explicitly so the next reader sees a decision rather than an oversight. It deliberately has no biological_scale and no downstream edges. Enuresis is deliberately left unwired, with its reason on the phenotype: the consensus lists it among supporting somatic signs and no cited source connects it to the basal ganglia process the other phenotypes hang off. Two dead references repaired rather than dropped. The entry cited DOI:10.2147/NDT.S362202 and DOI:10.1093/pch/pxy145, both of which cache with content_type unavailable and an empty body, so nothing could ever have been quoted from either. Both resolve to PubMed records with full text, PMID:37251418 and PMID:30996598, and are now cited in that form. Validation: just validate passes with 28/28 snippets verified, up from 5/5. Also run and read: validate-disorders, validate-terms, check-entity-refs, check-causal-targets, check-duplicate-keys, check-enum-values, check-qualifier-terms, check-case-collisions, check-folded-hyphens, check-snippet-length, check-title-snippets, check-snippet-grading, check-reference-titles, check-genereviews, list-gene-term-mismatches, validate-grouping, check-groupings, validate-history-all.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on Pediatric Acute-onset Neuropsychiatric Syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
Pediatric acute-onset neuropsychiatric syndrome (PANS) is a clinical, etiologically heterogeneous syndrome, not a single proven autoimmune disease. It is defined by an abrupt, dramatic onset—usually within 48 hours—of obsessive-compulsive disorder (OCD) and/or severely restricted food intake, accompanied by acute symptoms in at least two additional neuropsychiatric domains and not better explained by another disorder. PANDAS is the narrower proposed subgroup temporally associated with group A streptococcal infection (GAS). Current evidence supports immune-mediated disease in a subset, but no causal gene, pathogen, autoantibody, imaging signature, or laboratory test establishes the diagnosis. Accordingly, “autoimmune” is best treated as a proposed mechanism/subcategory, rather than an established property of every PANS case. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, trifiletti2022identificationofultrarare pages 1-2, wilbur2019pandaspansinchildhood pages 1-1)
The most current major source identified was the October 2024 Delphi consensus, which describes itself as providing updated shared clinical guidance but concludes that additional randomized controlled trials are required. Its abstract states: “Lights and shadows remain upon the management of children with PANS and PANDAS” and “more randomized and controlled trials are needed.” DOI: 10.3389/fimmu.2024.1420663. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5)
| domain | best-supported finding | suggested ontology terms/IDs (only where confident) | evidence type/strength | key citation DOI/PMID or NCT |
|---|---|---|---|---|
| Definition / criteria | PANS is a clinical syndrome defined by abrupt, dramatic onset of OCD or severely restricted food intake, plus at least 2 additional acute neuropsychiatric symptom categories, not better explained by another neurologic/medical disorder. Onset is typically described within 48 hours. | HPO: Obsessive-compulsive behavior; Food refusal / restricted intake; Anxiety; Emotional lability; Irritability; Developmental regression; Decline in school performance; Sensory disturbance; Sleep disturbance; Enuresis/urinary frequency. MAXO: not applicable. | Consensus/guideline and review evidence; moderate for criteria, low for biological specificity because criteria are syndromic and non-pathognomonic (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, wilbur2019pandaspansinchildhood pages 2-3, gagliano2023pediatricacuteonsetneuropsychiatric pages 2-4) | DOI:10.3389/fimmu.2024.1420663; PMID 25325534; DOI:10.2147/NDT.S362202 |
| Identifiers / nosology | MeSH term is present in ClinicalTrials-derived browse data as “Pediatric acute-onset neuropsychiatric syndrome.” MONDO/OMIM/Orphanet identifiers were not established from available evidence. PANS is not formally recognized as a DSM-5-TR standalone disorder. | MeSH: Pediatric acute-onset neuropsychiatric syndrome; MONDO: not established; OMIM: not established; Orphanet: not established. | Moderate for MeSH presence; low/unknown for cross-ontology mapping in available context (gagliano2023pediatricacuteonsetneuropsychiatric pages 1-2, NCT04508530 chunk 2, NCT02889016 chunk 1, NCT04609761 chunk 2) | NCT04508530; NCT02889016; NCT04609761 |
| Synonyms / related entities | Related terms include PANDAS (subset linked to streptococcal infection), Childhood Acute Neuropsychiatric Symptoms/CANS, and acute-onset OCD phenotype. PANDAS is considered a subset of PANS rather than a synonym. | No confident ontology IDs beyond MeSH term above. | Consensus/review; moderate (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16, NCT02190292 chunk 1) | DOI:10.3389/fimmu.2024.1420663; NCT02190292 |
| Core phenotypes | Reported frequencies in one cohort/review summary: obsessions/compulsions 89%, anxiety 78%, emotional lability/depression 71%, sleep disorders 69%, attention deficit 63%, tics 62%, motor abnormalities 60%, school decline 50%, sensory abnormalities 50%, irritability/aggression 44%, urinary frequency 44%, hyperactivity 43%, eating disorders 40%, behavioral regression 40%, pain 38%. | HPO suggestions: Obsessive-compulsive behavior; Anxiety; Depressed mood; Sleep disturbance; Tic; Abnormality of movement; Attention-deficit/hyperactivity; Learning or school difficulty; Sensory disturbance; Irritability; Urinary frequency; Food refusal. | Observational/cohort summarized in review; moderate for phenotype spectrum, low-moderate for exact frequencies across settings (gagliano2023pediatricacuteonsetneuropsychiatric pages 2-4, gagliano2023pediatricacuteonsetneuropsychiatric pages 1-2) | DOI:10.2147/NDT.S362202 |
| Age / sex distribution | Mean onset reported around 7±2 years; peak onset 5–12 years; male predominance around 2:1 has been reported. | HPO: Childhood onset. | Review/consensus; moderate (grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16, gagliano2023pediatricacuteonsetneuropsychiatric pages 1-2) | DOI:10.3389/fimmu.2024.1420663; DOI:10.2147/NDT.S362202 |
| Quality-of-life / functional burden | Symptoms can cause marked functional impairment, school decline, missed activities, and high caregiver burden; one sequencing paper states caregiver burden during first flare exceeds Alzheimer disease caregiving. | HPO: Impaired social/academic functioning; MAXO: supportive educational/psychological interventions. | Observational/review; moderate for substantial burden, low for cross-disease burden comparison generalizability (trifiletti2022identificationofultrarare pages 1-2, NCT04609761 chunk 1) | DOI:10.1038/s41598-022-15279-3; NCT04609761 |
| Epidemiology | True incidence/prevalence remain uncertain; available reviews emphasize lack of rigorous epidemiology, though PANS may account for at least 1 in 20 pediatric-onset OCD cases in some estimates. | Not applicable. | Low-moderate; estimate-based and heterogeneous (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, gagliano2023pediatricacuteonsetneuropsychiatric pages 2-4) | DOI:10.3389/fimmu.2024.1420663; DOI:10.2147/NDT.S362202 |
| Triggers: infectious | Infectious triggers reported include group A streptococcal infection, Mycoplasma pneumoniae, Borrelia burgdorferi, Staphylococcus aureus, and viral infections including Epstein-Barr, influenza, coxsackie, varicella, and SARS-CoV-2. PANDAS specifically requires temporal association with GAS. | CHEBI/NCBI Taxonomy not confidently assigned here. HPO: Postinfectious onset not available from provided evidence. | Review/consensus; moderate for association, low for proof of causality per pathogen (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16, gagliano2023pediatricacuteonsetneuropsychiatric pages 1-2) | DOI:10.3389/fimmu.2024.1420663; DOI:10.2147/NDT.S362202 |
| Triggers: noninfectious | Emotional stress and possible oxidative toxin exposure have been proposed as noninfectious triggers; these remain not established causal factors. | Not established. | Low/speculative (gagliano2023pediatricacuteonsetneuropsychiatric pages 1-2) | DOI:10.2147/NDT.S362202 |
| Genetics | No single causal gene is established for PANS. Candidate ultra-rare variants were reported in 11 genes in 21/396 sequenced cases: PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHEK2/CHK2, GRIN2A, RAG1, GABRG2, SYNGAP1. These are candidate susceptibility genes, not diagnostic or causal markers. | HGNC gene symbols: PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHEK2, GRIN2A, RAG1, GABRG2, SYNGAP1. | Human sequencing study; moderate for candidate-gene signal, low for causality/clinical validity (trifiletti2022identificationofultrarare pages 1-2) | DOI:10.1038/s41598-022-15279-3 |
| Family history / heritable predisposition | Increased family history of OCD, tics, and acute rheumatic fever has been reported; about 50% of cases may have pre-existing neurodevelopmental disorders, suggesting predisposition rather than monogenic inheritance. | HPO: Obsessive-compulsive behavior; Tic; Neurodevelopmental abnormality (general suggestion only). | Observational/review/consensus; low-moderate (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, trifiletti2022identificationofultrarare pages 1-2) | DOI:10.3389/fimmu.2024.1420663; DOI:10.1038/s41598-022-15279-3 |
| Pathophysiology: immune / autoimmune | Current leading model is infection- or inflammation-triggered neuroimmune dysregulation affecting brain circuits, but definitive autoimmune proof is lacking. Reported serum/CSF-associated markers include antibodies to dopamine D1/D2 receptors, lysoganglioside-GM1, β-tubulin, and elevated CaMKII activity; no biomarker is pathognomonic. | GO suggestions: immune response; inflammatory response; regulation of microglial activation; synaptic signaling. CL: microglial cell. | Review/consensus with inconsistent biomarker studies; low-moderate (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, gagliano2023pediatricacuteonsetneuropsychiatric pages 1-2, gagliano2023pediatricacuteonsetneuropsychiatric pages 22-23, wilbur2019pandaspansinchildhood pages 1-1) | DOI:10.3389/fimmu.2024.1420663; DOI:10.2147/NDT.S362202 |
| Pathophysiology: candidate mechanisms | Sequencing and model-based interpretations suggest convergence on peripheral immune signaling, microglia, synaptic function, and blood-CSF/brain barrier vulnerability. | GO suggestions: synaptic signaling; regulation of cytokine production; blood-brain barrier maintenance. CL: microglial cell; neuron. | Mechanistic hypothesis from human genetics/review; low-moderate (trifiletti2022identificationofultrarare pages 1-2) | DOI:10.1038/s41598-022-15279-3 |
| Anatomy / neuroanatomy | Neuroimaging abnormalities have been reported in thalamus, basal ganglia, amygdala, and putamen; basal ganglia circuitry is a recurrent focus in PANS/PANDAS literature. | UBERON suggestions: brain; basal ganglion; thalamus; amygdala; putamen. | Review/consensus/observational; moderate for implicated regions, low for specificity (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, trifiletti2022identificationofultrarare pages 1-2, NCT02889016 chunk 1, NCT04609761 chunk 1) | DOI:10.3389/fimmu.2024.1420663; DOI:10.1038/s41598-022-15279-3; NCT02889016; NCT04609761 |
| Cell types / tissue level | Microglia are repeatedly implicated in proposed neuroinflammatory models; neuronal synapses are implicated by candidate genes. Specific pathogenic cell type is not established in human tissue. | CL: microglial cell; neuron. GO: microglial activation; synaptic signaling. | Mechanistic/model-informed inference; low-moderate (trifiletti2022identificationofultrarare pages 1-2) | DOI:10.1038/s41598-022-15279-3 |
| Diagnostics: overall approach | Diagnosis is clinical and exclusionary. Recommended workup includes physical, psychiatric, neurologic, and neuropsychological evaluation; targeted laboratory testing; and MRI/EEG/sleep evaluation, with CSF analysis reserved for severe or encephalitic presentations. | MAXO: MRI; EEG; cerebrospinal fluid examination; cognitive behavioral therapy assessment not an ontology certainty here. | Consensus/review; moderate (gagliano2023pediatricacuteonsetneuropsychiatric pages 22-23, NCT02889016 chunk 1, NCT04609761 chunk 1) | DOI:10.2147/NDT.S362202; NCT02889016; NCT04609761 |
| Diagnostics: biomarkers | Infectious parameters have the strongest practical support when infection is suspected. D1/D2 receptor antibodies, lyso-GM1, β-tubulin, and CaMKII activity have been reported, but individual biomarkers lack sufficient sensitivity/specificity for diagnosis; no validated standalone biomarker exists. Cunningham panel utility remains uncertain. | No confident ontology IDs. | Moderate that no validated biomarker exists; low for specific assay clinical utility (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, gagliano2023pediatricacuteonsetneuropsychiatric pages 22-23, NCT02190292 chunk 1) | DOI:10.3389/fimmu.2024.1420663; DOI:10.2147/NDT.S362202; NCT02190292 |
| Differential diagnosis | Important exclusions include Sydenham chorea, autoimmune encephalitis/encephalitis, systemic lupus erythematosus, Tourette disorder, primary OCD, psychotic disorders, autism-related regression, and other neurologic/medical causes. | HPO/ontology not enumerated from evidence. | Consensus/guideline; moderate (wilbur2019pandaspansinchildhood pages 2-3, NCT04508530 chunk 1, NCT04609761 chunk 2) | PMID 25325534; NCT04508530; NCT04609761 |
| Disease course | Often acute/subacute at onset with episodic, relapsing-remitting, or chronic progressive/disintegrative course; stabilization between flares may occur. | HPO: Episodic course; relapsing-remitting course (general suggestions). | Review/consensus; moderate (wilbur2019pandaspansinchildhood pages 2-3, gagliano2023pediatricacuteonsetneuropsychiatric pages 1-2, NCT04508530 chunk 1) | DOI:10.2147/NDT.S362202; NCT04508530 |
| Prognosis / natural history | Long-term natural history is incompletely defined; some children improve substantially over time, but reviews caution that improvement may reflect fluctuating natural course rather than treatment effect alone. | Not applicable. | Low-moderate (wilbur2019pandaspansinchildhood pages 4-4, wilbur2019pandaspansinchildhood pages 5-6, NCT02190292 chunk 1) | DOI:10.1093/pch/pxy145; NCT02190292 |
| First-line symptomatic treatment | CBT/ERP and SSRIs are commonly recommended first-line symptomatic treatments for OCD/anxiety symptoms; consensus advises not delaying psychiatric treatment while etiologic workup proceeds. Medication intolerance/sensitivity may be higher than in typical pediatric psychiatric populations. | MAXO suggestions: cognitive behavioral therapy; selective serotonin reuptake inhibitor therapy. | Consensus plus small studies/observational evidence; moderate for use, low-moderate for disease-specific efficacy (grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16, gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20, gagliano2023pediatricacuteonsetneuropsychiatric pages 20-22, NCT01617083 chunk 2) | DOI:10.3389/fimmu.2024.1420663; DOI:10.2147/NDT.S362202; NCT01617083 |
| Antibiotics | Antibiotics are recommended when active infection is identified. Evidence for disease-modifying benefit without active infection is mixed: a 4-week randomized azithromycin trial exists; long-term prophylaxis is not well supported. | MAXO suggestion: antibiotic therapy. | Moderate for treating documented infection; low-moderate for psychiatric symptom benefit beyond infection control (gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20, wilbur2019pandaspansinchildhood pages 3-4, gagliano2023pediatricacuteonsetneuropsychiatric pages 20-22, NCT01617083 chunk 1, NCT01617083 chunk 2) | NCT01617083; DOI:10.1093/pch/pxy145; DOI:10.2147/NDT.S362202 |
| NSAIDs / corticosteroids | NSAIDs and short corticosteroid courses are used in some protocols, especially mild to moderate inflammatory presentations, but evidence is limited and largely observational/consensus-based. | MAXO suggestions: nonsteroidal anti-inflammatory drug therapy; corticosteroid therapy. | Low-moderate (grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16, wilbur2019pandaspansinchildhood pages 3-4) | DOI:10.3389/fimmu.2024.1420663; DOI:10.1093/pch/pxy145 |
| IVIG | IVIG is frequently used for moderate-to-severe or selected inflammatory PANS in expert protocols. Evidence includes older small controlled studies, observational/open-label studies, and recent/ongoing phase 2-3 trials; benefit remains debated and not definitively established. | MAXO suggestion: intravenous immunoglobulin therapy. | Moderate for clinical use; low-moderate for definitive efficacy due to heterogeneous and limited trials (gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20, wilbur2019pandaspansinchildhood pages 3-4, wilbur2019pandaspansinchildhood pages 4-4, NCT04508530 chunk 1, NCT04609761 chunk 1, NCT04609761 chunk 2) | NCT04508530; NCT04609761; DOI:10.1093/pch/pxy145 |
| Plasma exchange | Therapeutic plasma exchange is reserved in expert guidance for extreme/life-threatening impairment; observational data suggest improvement in severe cases, but controlled evidence is limited. | MAXO suggestion: therapeutic plasma exchange. | Low-moderate (gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20, wilbur2019pandaspansinchildhood pages 4-4) | DOI:10.2147/NDT.S362202; DOI:10.1093/pch/pxy145 |
| Rituximab / other immunomodulators | Rituximab is not routinely recommended for PANS and is generally reserved, if at all, for definite autoimmune encephalitis or highly selected refractory cases. Evidence in PANS specifically is minimal/not established. | MAXO suggestion: rituximab therapy. | Low/not established (gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20, grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16, NCT04508530 chunk 2) | DOI:10.2147/NDT.S362202; NCT04508530 |
| Adverse effects / safety | IVIG adverse effects include nausea, myalgia, fever, chills/rigors, chest discomfort, hypotension, headache. Azithromycin trial protocols monitored hepatic toxicity and QTc prolongation. Psychotropics may require dose changes due to side effects in a high proportion of patients. | MAXO: adverse event monitoring; ECG monitoring; liver function monitoring. | Moderate for expected treatment-related adverse effects from protocols/reviews (gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20, gagliano2023pediatricacuteonsetneuropsychiatric pages 20-22, NCT01617083 chunk 2, NCT04609761 chunk 1) | NCT01617083; NCT04609761; DOI:10.2147/NDT.S362202 |
| Prevention | No established primary prevention exists for PANS. Prevention of recurrent infectious triggers and prompt treatment of active infections are used pragmatically. A 2024 consensus mentions vitamin D prophylaxis suggestion, but this is not established standard-of-care. | MAXO suggestions: infection prevention/treatment; vitamin supplementation (vitamin D) only as low-confidence suggestion. | Low (grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16) | DOI:10.3389/fimmu.2024.1420663 |
| Real-world research implementation | Active real-world studies include biomarker discovery, longitudinal cohort characterization, and interventional trials: Stanford biomarker cohort (500 planned; NCT02889016), Scandinavian cohort (NCT02190292), azithromycin RCT (NCT01617083), IVIG open-label study (NCT04609761), and phase III Panzyga crossover trial (NCT04508530). | Not applicable. | Strong for existence of implementation/trials (NCT01617083 chunk 1, NCT04508530 chunk 1, NCT02889016 chunk 1, NCT04609761 chunk 1, NCT02190292 chunk 1) | NCT02889016; NCT02190292; NCT01617083; NCT04609761; NCT04508530 |
| Evidence gaps / unknowns | Not established: single causal gene, validated diagnostic biomarker, prevalence/incidence, definitive autoimmune mechanism, standardized evidence-based treatment hierarchy, or disease-specific prevention strategy. | MONDO/OMIM/Orphanet IDs not established from available evidence. | Strong agreement across reviews/consensus that major gaps remain (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, gagliano2023pediatricacuteonsetneuropsychiatric pages 22-23, wilbur2019pandaspansinchildhood pages 1-1, wilbur2019pandaspansinchildhood pages 5-6) | DOI:10.3389/fimmu.2024.1420663; DOI:10.2147/NDT.S362202; DOI:10.1093/pch/pxy145 |
Table: This compact table summarizes the best-supported current findings for Pediatric Acute-onset Neuropsychiatric Syndrome across definition, phenotypes, triggers, candidate genetics, mechanisms, diagnostics, course, and treatment. It explicitly distinguishes established clinical criteria from areas that remain uncertain or unvalidated.
The working criteria are:
PANS is therefore a syndrome of presentation and exclusion. PANDAS additionally requires childhood onset, an episodic course, temporal association with GAS, and neurologic abnormalities such as motor hyperactivity or choreiform movements. It should be represented as a PANS-related subset, not as an exact synonym. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, NCT04508530 chunk 1)
The evidence summarized here is aggregated disease-level evidence from consensus statements, cohorts, trials, and reviews. Clinical recognition in practice is based on individual history, examination, records, and targeted testing—not an EHR-derived computable phenotype alone.
No single cause is established. The leading framework is a susceptible child plus an infectious, inflammatory, or other stressor, followed by neuroimmune and circuit dysfunction. Reported infectious associations include GAS, Mycoplasma pneumoniae, Borrelia burgdorferi, Staphylococcus aureus, Epstein–Barr virus, influenza, coxsackievirus, varicella-zoster virus, and SARS-CoV-2. Temporal association does not prove microbial causation, and PANS does not require infection. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16, gagliano2023pediatricacuteonsetneuropsychiatric pages 1-2)
Emotional stress and possible oxidative/toxic exposures have been proposed, but evidence is sparse and insufficient for causal attribution. Lifestyle factors such as diet, exercise, smoking, or alcohol have no established disease-specific role. Proposed streptococcal-associated gut dysbiosis is mechanistically plausible but remains investigational. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, gagliano2023pediatricacuteonsetneuropsychiatric pages 1-2)
Family histories reportedly contain excess OCD, tic disorders, and acute rheumatic fever. Pre-existing neurodevelopmental disorders occur in substantial fractions of clinical cohorts; the 2024 consensus cites approximately 50%, while 12 of 21 genetically selected cases with candidate variants had a neurodevelopmental disorder. These observations support susceptibility but not Mendelian inheritance. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, trifiletti2022identificationofultrarare pages 1-2)
A plausible gene–environment chain is: immune/synaptic/barrier susceptibility → infection or inflammatory stress → peripheral immune activation and altered barrier function → microglial, antibody, or cytokine effects on cortico-striato-thalamo-cortical circuits → OCD, eating restriction, tics, affective symptoms, and cognitive dysfunction. Each intermediate step remains incompletely validated in human PANS. (trifiletti2022identificationofultrarare pages 1-2, gagliano2023pediatricacuteonsetneuropsychiatric pages 22-23)
No reproducible genetic protective variant, diet, behavior, exposure, or prophylactic intervention is established. A 2024 Delphi statement suggested vitamin D prophylaxis, but this is consensus-level rather than trial-supported evidence and should not be encoded as proven prevention. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16)
One review’s cohort summary reported obsessions/compulsions in 89%, anxiety 78%, emotional lability/depression 71%, sleep disorders 69%, attention deficit 63%, tics 62%, motor abnormalities 60%, decline in school performance 50%, sensory abnormalities 50%, urinary frequency 44%, irritability/aggression 44%, hyperactivity 43%, eating disorders 40%, developmental regression 40%, and pain 38%. These frequencies are cohort-dependent and should not be generalized as population prevalence. (gagliano2023pediatricacuteonsetneuropsychiatric pages 2-4)
Suggested HPO annotations include obsessive-compulsive behavior, anxiety, depressed mood, emotional lability, irritability, aggression, tic, abnormal involuntary movement, attention deficit/hyperactivity, developmental regression, sleep disturbance, urinary frequency, enuresis, food refusal/restricted intake, sensory disturbance, pain, and childhood onset. Exact HPO identifiers should be validated against the current HPO release before database loading.
Severity ranges from mild impairment to extreme or life-threatening illness, including inability to eat, suicidality, severe aggression, or profound functional collapse. The course is commonly fluctuating or episodic. School participation, family functioning, adaptive behavior, and quality of life can be markedly impaired; one genetics paper reported caregiver burden during the first flare exceeding that reported for Alzheimer-disease caregiving, although this comparison requires replication. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, trifiletti2022identificationofultrarare pages 1-2, NCT02889016 chunk 1)
PANS has no validated causal gene, pathogenic variant set, inheritance pattern, penetrance estimate, carrier frequency, founder mutation, or diagnostic genetic test. Therefore, ClinVar-style pathogenic classification for “PANS variants” is not currently appropriate.
A 2022 human WES/WGS study examined 386 US cases and 10 severe European cases. Twenty-one cases carried candidate de novo or ultra-rare variants (minor-allele frequency <0.001) in 11 genes: PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHEK2, GRIN2A, RAG1, GABRG2, and SYNGAP1. The authors grouped these into immune/microglial genes and neuronal/synaptic genes. These are hypothesis-generating susceptibility candidates—not clinically validated PANS genes or ACMG-pathogenic variants for this syndrome. DOI: 10.1038/s41598-022-15279-3. (trifiletti2022identificationofultrarare pages 1-2)
No reproducible PANS-specific epigenetic signature, chromosomal abnormality, somatic mutation, repeat expansion, mitochondrial defect, or modifier gene has been established. WES/WGS may be appropriate when an alternative neurodevelopmental, epileptic, metabolic, or immunologic disorder is suspected, but it is not a confirmatory PANS test.
The principal non-genetic evidence concerns infections and inflammatory stressors. GAS is specifically relevant to PANDAS, whereas PANS can follow multiple infections or no identified infection. Testing and treatment should therefore be directed by symptoms and exposure history rather than indiscriminate pathogen panels. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, gagliano2023pediatricacuteonsetneuropsychiatric pages 1-2, NCT01617083 chunk 1)
There is no established association with occupational exposure, radiation, air pollution, smoking, alcohol, or a specific dietary pattern. No zoonotic transmission or person-to-person transmission of PANS exists; transmissible infections may act as triggers, but the syndrome itself is noncommunicable.
Reported antibody-related signals include dopamine D1/D2 receptor, lysoganglioside-GM1, β-tubulin antibodies, and CaMKII activation. However, studies are inconsistent, these findings are not specific to PANS, and no antibody is pathognomonic. The 2019 critical review states that “definitive proof of the autoimmune hypothesis of PANDAS is lacking.” (gagliano2023pediatricacuteonsetneuropsychiatric pages 22-23, wilbur2019pandaspansinchildhood pages 1-1)
Suggested biological-process annotations are immune response, inflammatory response, cytokine production, microglial activation, regulation of blood–brain barrier permeability, dopaminergic receptor signaling, synaptic signaling, and learning/memory. Suggested cell types are microglial cell, neuron, brain microvascular endothelial cell, T lymphocyte, B lymphocyte, monocyte/macrophage, and choroid-plexus epithelial cell; only microglial and neuronal involvement has substantial support in the retrieved PANS literature. (trifiletti2022identificationofultrarare pages 1-2)
Human transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, and CRISPR-screen signatures are not sufficiently replicated for clinical annotation. The Stanford prospective cohort plans PBMC collection for GWAS, CyTOF, T-cell-receptor analysis, antibody profiling, and monocyte characterization, illustrating current real-world multi-omic research rather than validated diagnostics. NCT02889016. (NCT02889016 chunk 1)
The primary system is the CNS. Imaging and mechanistic studies implicate the basal ganglia/putamen, thalamus, and amygdala, although findings are neither universal nor diagnostic. Suggested UBERON concepts are brain, basal ganglion, putamen, thalamus, amygdala, cerebral cortex, choroid plexus, and brain microvasculature. No consistent lateralization is established. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, trifiletti2022identificationofultrarare pages 1-2)
At the tissue/cellular level, proposed sites include neural synapses, microglia, neurovascular endothelium, and the blood–CSF interface. No characteristic biopsy pathology or subcellular lesion is established; brain biopsy is not part of routine diagnosis.
Mean onset has been reported near 7±2 years, with a peak around 5–12 years; boys may outnumber girls approximately 2:1. The defining onset is abrupt, often within 48 hours. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16, gagliano2023pediatricacuteonsetneuropsychiatric pages 1-2)
Subsequent courses include monophasic improvement, episodic flares, relapsing-remitting disease, and chronic or progressive/disintegrative patterns. There is no accepted stage system. Long-term duration and remission probabilities remain uncertain, and apparent therapeutic response must be interpreted against spontaneous fluctuation. Early recognition is important for safety, nutrition, restoration of school/family function, and treatment of identifiable infection or inflammatory disease, but a formally validated therapeutic window has not been established. (wilbur2019pandaspansinchildhood pages 2-3, gagliano2023pediatricacuteonsetneuropsychiatric pages 1-2, wilbur2019pandaspansinchildhood pages 4-4)
No reliable incidence or prevalence per 100,000 is available. A review suggested PANS might represent at least 1 in 20 pediatric-onset OCD cases, but rigorous population ascertainment is lacking. Thus, this is not an appropriate substitute for population prevalence. (gagliano2023pediatricacuteonsetneuropsychiatric pages 2-4)
Reported demographics include childhood onset and male predominance. No robust ethnic, founder, geographic, consanguinity, anticipation, mosaicism, or carrier-frequency pattern is known. Inheritance is best classified as unknown/multifactorial susceptibility, not autosomal dominant, recessive, X-linked, or mitochondrial.
Diagnosis requires a detailed timeline documenting the abrupt onset; psychiatric assessment including CY-BOCS where OCD is present; neurologic and pediatric examination; nutritional and safety assessment; and exclusion of alternative causes. Neuropsychological, school, sleep, and functional evaluation may quantify impairment. (gagliano2023pediatricacuteonsetneuropsychiatric pages 22-23, NCT02889016 chunk 1)
Laboratory testing should be hypothesis-driven: throat culture or rapid testing when GAS is suspected; paired streptococcal serology where clinically informative; CBC, metabolic profile, inflammatory markers, urinalysis, and testing for other infection, autoimmune disease, immunodeficiency, endocrinopathy, or metabolic disease as indicated. A positive infectious marker documents exposure/infection, not PANS causation. (gagliano2023pediatricacuteonsetneuropsychiatric pages 22-23, NCT01617083 chunk 1)
MRI, EEG, polysomnography, or CSF examination are not routine confirmatory tests but may be warranted for focal neurologic findings, seizures, altered consciousness, psychosis, severe motor disorder, encephalitic features, or atypical progression. The Swedish IVIG protocol specifically required CSF evaluation when encephalitis could not otherwise be excluded. (NCT04609761 chunk 1, NCT04609761 chunk 2)
No validated diagnostic biomarker exists. The Cunningham panel and D1/D2, lysoganglioside-GM1, β-tubulin, and CaMKII assays lack sufficient demonstrated sensitivity, specificity, and external validation for standalone diagnosis. A Scandinavian study was expressly designed to evaluate Cunningham-panel sensitivity and specificity, reflecting unresolved clinical utility. NCT02190292. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, gagliano2023pediatricacuteonsetneuropsychiatric pages 22-23, NCT02190292 chunk 1)
WES, WGS, panels, CMA, karyotyping, FISH, mitochondrial testing, and repeat-expansion testing are not PANS tests. They should be selected only to evaluate a plausible alternative genetic diagnosis.
Key exclusions include primary OCD/eating disorder, tic or Tourette disorder, Sydenham chorea, autoimmune encephalitis, acute disseminated encephalomyelitis, epilepsy, systemic lupus erythematosus or CNS vasculitis, infectious encephalitis, Wilson disease, thyroid/metabolic disease, medication or substance effects, psychotic/bipolar disorders, functional neurologic disorder, and neurodevelopmental regression. Red flags—altered consciousness, seizures, focal deficits, autonomic instability, frank chorea, catatonia, or progressive cognitive decline—warrant urgent neurologic/encephalitis evaluation. (wilbur2019pandaspansinchildhood pages 2-3, NCT04508530 chunk 1, NCT04609761 chunk 2)
There is no asymptomatic population, newborn, carrier, prenatal, or cascade screening program.
PANS is not generally considered a primary fatal disorder, and disease-specific survival or mortality estimates are unavailable. Serious morbidity can arise from malnutrition/dehydration, suicidality, aggression, medication or immunotherapy complications, school loss, family disruption, and chronic psychiatric disability.
Recovery can be substantial, but the proportion achieving durable remission is uncertain. Studies have reported 60–80% symptom reduction over time in some cohorts, yet critical reviewers caution that this can reflect natural fluctuation, concurrent psychiatric treatment, or regression to the mean. Reliable prognostic biomarkers do not exist. Plausible adverse prognostic features include severe functional impairment, prolonged untreated symptoms, recurrent triggers, comorbid neurodevelopmental disease, and inability to restore nutrition or participation, but validated prediction models are absent. (wilbur2019pandaspansinchildhood pages 4-4, wilbur2019pandaspansinchildhood pages 5-6)
Treatment should be individualized along three parallel tracks: (1) safety and symptom-directed psychiatric/behavioral care; (2) identification and standard treatment of active infection or another medical cause; and (3) anti-inflammatory/immunomodulatory treatment only for carefully selected cases with credible inflammatory or autoimmune disease. Neuropsychiatric treatment should not be delayed while etiologic testing proceeds. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16)
CBT with exposure and response prevention (ERP) and cautious SSRI use are first-line approaches for OCD/anxiety. One small study reported response in all 8 participants and remission in 6; another reported significant OCD reduction in 33/62 after one year, without improvement in tic severity. These uncontrolled/small studies support feasibility rather than PANS-specific superiority. Suggested MAXO mappings: cognitive behavioral therapy, exposure-and-response prevention, psychiatric assessment, nutritional support, occupational therapy, and educational intervention. (gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20, wilbur2019pandaspansinchildhood pages 3-3)
Psychotropics should be started low and titrated slowly. In one observational series, 54% experienced side effects requiring medication changes; rates were 38% for antidepressants and 49% for antipsychotics. (gagliano2023pediatricacuteonsetneuropsychiatric pages 20-22)
Treat documented infections according to ordinary pediatric infectious-disease standards. A four-week randomized azithromycin study of 31 PANS children showed greater OCD-severity reduction than placebo but not broad improvement across other neuropsychiatric outcomes. The registered phase 2 study enrolled 47 participants aged 4–14 and monitored liver toxicity and QTc prolongation. NCT01617083. (wilbur2019pandaspansinchildhood pages 3-3, NCT01617083 chunk 1, NCT01617083 chunk 2)
Evidence for prophylaxis is conflicting: one placebo-controlled penicillin study (n=37) did not reduce exacerbations or tic/OCD severity, whereas a small azithromycin/penicillin study (n=23) reported 96% fewer GAS infections and 61% fewer exacerbations. Routine long-term antibiotics without documented infection are therefore not supported by strong evidence. (wilbur2019pandaspansinchildhood pages 3-4, gagliano2023pediatricacuteonsetneuropsychiatric pages 20-22, wilbur2019pandaspansinchildhood pages 5-6)
NSAIDs and short corticosteroid bursts are used by specialty programs, but evidence is mostly retrospective. In one observational corticosteroid study (n=98), flares were approximately 3.5 weeks shorter; confounding and indication bias limit inference. (wilbur2019pandaspansinchildhood pages 3-4, grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16)
IVIG is used in selected moderate-to-severe inflammatory cases, but older controlled studies showed substantial placebo response and inconsistent separation from placebo. Open-label reports have described 50–55% mean CY-BOCS reduction and 67–80% responder rates by 24 weeks in a 24-patient series, but uncontrolled design and fluctuating disease course weaken causal interpretation. Common infusion reactions include headache, nausea, myalgia, fever, chills/rigors, chest discomfort, and hypotension; rare serious risks include thrombosis, renal injury, hemolysis, aseptic meningitis, and anaphylaxis. (gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20, wilbur2019pandaspansinchildhood pages 3-4, wilbur2019pandaspansinchildhood pages 4-4)
A phase III randomized, quadruple-masked crossover trial of Panzyga 10% IVIG versus placebo enrolled 71 patients aged 6–17; the primary endpoint was percentage CY-BOCS change at week 9. It completed in 2024, but the retrieved 2024 evidence did not provide peer-reviewed outcome data, so no efficacy conclusion should be inferred here. NCT04508530. (NCT04508530 chunk 1, NCT04508530 chunk 2)
An open-label Swedish phase 2 study administered IVIG 2 g/kg every four weeks for six months and assessed PANS severity, CY-BOCS, adaptive function, quality of life, cognition, school absence, and caregiver burden; its nonrandomized design limits causal inference. NCT04609761; related publication PMID 35933358. (NCT04609761 chunk 1, NCT04609761 chunk 2)
Therapeutic plasma exchange is reserved by some experts for extreme/life-threatening cases. A 35-patient severe-case series reported approximately 65% improvement at six months and 78% at longer follow-up, but this is observational. Rituximab, mycophenolate, and other sustained immunosuppression lack adequate PANS-specific evidence; Nordic guidance cited in the review advises against rituximab except where definite autoimmune encephalitis warrants it. (gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20, wilbur2019pandaspansinchildhood pages 5-6)
Tonsillectomy/adenoidectomy is not supported as PANS/PANDAS therapy: studies comparing 20 surgical with 23 nonsurgical patients and a prospective cohort of 120 found no meaningful advantage in remission, relapse, symptom severity, or antibody titers. (wilbur2019pandaspansinchildhood pages 4-4)
No gene therapy, cell therapy, RNA therapeutic, surgery, or genotype-guided pharmacotherapy is established. Pharmacogenomic recommendations are the same as for the medication being used; there is no PANS-specific CPIC pathway.
No proven primary prevention exists. Standard vaccination and prompt, guideline-concordant diagnosis and treatment of infections remain appropriate; evidence does not justify withholding routine immunization. Antibiotic prophylaxis is not routinely recommended because controlled evidence is inconsistent and risks include adverse reactions, microbiome disruption, C. difficile, and antimicrobial resistance. (wilbur2019pandaspansinchildhood pages 3-4, wilbur2019pandaspansinchildhood pages 5-6)
Secondary/tertiary prevention consists of early recognition of abrupt symptoms, safety and nutritional assessment, rapid treatment of confirmed infection, restoration of sleep and school participation, family education, relapse planning, and maintenance CBT/ERP skills. There is no validated genetic counseling or reproductive-risk protocol because no Mendelian inheritance is established.
No naturally occurring veterinary disease has been established as a direct PANS homolog, and no breed, VBO identifier, cross-species transmission pattern, or zoonotic PANS risk is recognized. Animal neurobehavioral syndromes following infection may offer analogies, but they should not be encoded as spontaneous PANS.
The principal experimental analog is a GAS-exposure/immunization rodent model developed to study Sydenham chorea/PANDAS-like mechanisms. Streptococcal exposure in rats produced behavioral, pharmacologic, and immunologic abnormalities; the relevant primary publication is Brimberg et al., 2012, PMID 22534626, DOI: 10.1038/npp.2012.56. (NCT02190292 chunk 1)
Passive-transfer and immunization studies support the possibility that anti-streptococcal antibodies can bind neural targets and alter behavior when CNS access is permitted. Their principal applications are molecular mimicry, blood–brain-barrier entry, basal-ganglia antibody binding, dopaminergic signaling, and microglial activation. Limitations are substantial: induced exposure is not equivalent to clinically heterogeneous PANS; rodent behaviors are imperfect proxies for OCD, regression, and restricted eating; and these models do not establish that the same mechanism operates in most human cases. (trifiletti2022identificationofultrarare pages 1-2, wilbur2019pandaspansinchildhood pages 1-1)
The most defensible current interpretation is that PANS is a useful acute-onset clinical phenotype requiring urgent, multidisciplinary evaluation. Evidence is strongest for the reproducibility of its symptom pattern, functional burden, and need for standard psychiatric and medical care. Evidence is intermediate for infection/inflammation as triggers in a subset. Evidence remains weak or inconsistent for a unitary autoimmune mechanism, commercial autoantibody panels, chronic antibiotic prophylaxis, and routine immunotherapy. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, gagliano2023pediatricacuteonsetneuropsychiatric pages 22-23, wilbur2019pandaspansinchildhood pages 1-1, wilbur2019pandaspansinchildhood pages 5-6)
Key recent sources are Gagliano et al., May 2023, DOI 10.2147/NDT.S362202, and Grandinetti et al., October 2024, DOI 10.3389/fimmu.2024.1420663. The latter is expert consensus, not a replacement for randomized evidence. Major knowledge-base fields that should remain explicitly unknown/not established are MONDO/OMIM/Orphanet mapping, incidence and prevalence, causal genes and variants, validated biomarker, definitive autoimmune mechanism, formal staging, survival estimates, prognostic biomarkers, and proven primary prevention. (grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5, gagliano2023pediatricacuteonsetneuropsychiatric pages 2-4, gagliano2023pediatricacuteonsetneuropsychiatric pages 22-23)
References
(grandinetti2024pediatricacuteonsetneuropsychiatric pages 4-5): Roberto Grandinetti, Nicole Mussi, Simone Pilloni, Greta Ramundo, Angela Miniaci, Emanuela Turco, Benedetta Piccolo, Maria Elena Capra, Roberta Forestiero, Serena Laudisio, Giovanni Boscarino, Laura Pedretti, Martina Menoni, Giuditta Pellino, Silvia Tagliani, Andrea Bergomi, Francesco Antodaro, Maria Cristina Cantù, Maria Teresa Bersini, Sandra Mari, Franco Mazzini, Giacomo Biasucci, Agnese Suppiej, and Susanna Esposito. Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up. Frontiers in Immunology, Oct 2024. URL: https://doi.org/10.3389/fimmu.2024.1420663, doi:10.3389/fimmu.2024.1420663. This article has 15 citations and is from a peer-reviewed journal.
(trifiletti2022identificationofultrarare pages 1-2): Rosario Trifiletti, Herbert M. Lachman, Olivia Manusama, Deyou Zheng, Alberto Spalice, Pietro Chiurazzi, Allan Schornagel, Andreea M. Serban, Rogier van Wijck, Janet L. Cunningham, Sigrid Swagemakers, and Peter J. van der Spek. Identification of ultra-rare genetic variants in pediatric acute onset neuropsychiatric syndrome (pans) by exome and whole genome sequencing. Scientific Reports, Jun 2022. URL: https://doi.org/10.1038/s41598-022-15279-3, doi:10.1038/s41598-022-15279-3. This article has 44 citations and is from a peer-reviewed journal.
(wilbur2019pandaspansinchildhood pages 1-1): Colin Wilbur, Ari Bitnun, Sefi Kronenberg, Ronald M Laxer, Deborah M Levy, William J Logan, Michelle Shouldice, and E Ann Yeh. Pandas/pans in childhood: controversies and evidence. Paediatrics & child health, 24 2:85-91, Dec 2019. URL: https://doi.org/10.1093/pch/pxy145, doi:10.1093/pch/pxy145. This article has 117 citations and is from a peer-reviewed journal.
(wilbur2019pandaspansinchildhood pages 2-3): Colin Wilbur, Ari Bitnun, Sefi Kronenberg, Ronald M Laxer, Deborah M Levy, William J Logan, Michelle Shouldice, and E Ann Yeh. Pandas/pans in childhood: controversies and evidence. Paediatrics & child health, 24 2:85-91, Dec 2019. URL: https://doi.org/10.1093/pch/pxy145, doi:10.1093/pch/pxy145. This article has 117 citations and is from a peer-reviewed journal.
(gagliano2023pediatricacuteonsetneuropsychiatric pages 2-4): Antonella Gagliano, Alessandra Carta, Marcello G Tanca, and Stefano Sotgiu. Pediatric acute-onset neuropsychiatric syndrome: current perspectives. Neuropsychiatric Disease and Treatment, 19:1221-1250, May 2023. URL: https://doi.org/10.2147/ndt.s362202, doi:10.2147/ndt.s362202. This article has 60 citations and is from a peer-reviewed journal.
(gagliano2023pediatricacuteonsetneuropsychiatric pages 1-2): Antonella Gagliano, Alessandra Carta, Marcello G Tanca, and Stefano Sotgiu. Pediatric acute-onset neuropsychiatric syndrome: current perspectives. Neuropsychiatric Disease and Treatment, 19:1221-1250, May 2023. URL: https://doi.org/10.2147/ndt.s362202, doi:10.2147/ndt.s362202. This article has 60 citations and is from a peer-reviewed journal.
(NCT04508530 chunk 2): Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS). Octapharma. 2021. ClinicalTrials.gov Identifier: NCT04508530
(NCT02889016 chunk 1): Jennifer Frankovich. Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS. Stanford University. 2013. ClinicalTrials.gov Identifier: NCT02889016
(NCT04609761 chunk 2): Open-label Trial of IVIG in Children With PANS. Göteborg University. 2021. ClinicalTrials.gov Identifier: NCT04609761
(grandinetti2024pediatricacuteonsetneuropsychiatric pages 16-16): Roberto Grandinetti, Nicole Mussi, Simone Pilloni, Greta Ramundo, Angela Miniaci, Emanuela Turco, Benedetta Piccolo, Maria Elena Capra, Roberta Forestiero, Serena Laudisio, Giovanni Boscarino, Laura Pedretti, Martina Menoni, Giuditta Pellino, Silvia Tagliani, Andrea Bergomi, Francesco Antodaro, Maria Cristina Cantù, Maria Teresa Bersini, Sandra Mari, Franco Mazzini, Giacomo Biasucci, Agnese Suppiej, and Susanna Esposito. Pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections: a delphi study and consensus document about definition, diagnostic criteria, treatment and follow-up. Frontiers in Immunology, Oct 2024. URL: https://doi.org/10.3389/fimmu.2024.1420663, doi:10.3389/fimmu.2024.1420663. This article has 15 citations and is from a peer-reviewed journal.
(NCT02190292 chunk 1): Susanne Bejerot. PANS - A Detailed Study of the Patients, Their Symptoms, Biomarkers and Treatment Offered in a Scandinavian Cohort. Karolinska Institutet. 2014. ClinicalTrials.gov Identifier: NCT02190292
(NCT04609761 chunk 1): Open-label Trial of IVIG in Children With PANS. Göteborg University. 2021. ClinicalTrials.gov Identifier: NCT04609761
(gagliano2023pediatricacuteonsetneuropsychiatric pages 22-23): Antonella Gagliano, Alessandra Carta, Marcello G Tanca, and Stefano Sotgiu. Pediatric acute-onset neuropsychiatric syndrome: current perspectives. Neuropsychiatric Disease and Treatment, 19:1221-1250, May 2023. URL: https://doi.org/10.2147/ndt.s362202, doi:10.2147/ndt.s362202. This article has 60 citations and is from a peer-reviewed journal.
(NCT04508530 chunk 1): Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS). Octapharma. 2021. ClinicalTrials.gov Identifier: NCT04508530
(wilbur2019pandaspansinchildhood pages 4-4): Colin Wilbur, Ari Bitnun, Sefi Kronenberg, Ronald M Laxer, Deborah M Levy, William J Logan, Michelle Shouldice, and E Ann Yeh. Pandas/pans in childhood: controversies and evidence. Paediatrics & child health, 24 2:85-91, Dec 2019. URL: https://doi.org/10.1093/pch/pxy145, doi:10.1093/pch/pxy145. This article has 117 citations and is from a peer-reviewed journal.
(wilbur2019pandaspansinchildhood pages 5-6): Colin Wilbur, Ari Bitnun, Sefi Kronenberg, Ronald M Laxer, Deborah M Levy, William J Logan, Michelle Shouldice, and E Ann Yeh. Pandas/pans in childhood: controversies and evidence. Paediatrics & child health, 24 2:85-91, Dec 2019. URL: https://doi.org/10.1093/pch/pxy145, doi:10.1093/pch/pxy145. This article has 117 citations and is from a peer-reviewed journal.
(gagliano2023pediatricacuteonsetneuropsychiatric pages 18-20): Antonella Gagliano, Alessandra Carta, Marcello G Tanca, and Stefano Sotgiu. Pediatric acute-onset neuropsychiatric syndrome: current perspectives. Neuropsychiatric Disease and Treatment, 19:1221-1250, May 2023. URL: https://doi.org/10.2147/ndt.s362202, doi:10.2147/ndt.s362202. This article has 60 citations and is from a peer-reviewed journal.
(gagliano2023pediatricacuteonsetneuropsychiatric pages 20-22): Antonella Gagliano, Alessandra Carta, Marcello G Tanca, and Stefano Sotgiu. Pediatric acute-onset neuropsychiatric syndrome: current perspectives. Neuropsychiatric Disease and Treatment, 19:1221-1250, May 2023. URL: https://doi.org/10.2147/ndt.s362202, doi:10.2147/ndt.s362202. This article has 60 citations and is from a peer-reviewed journal.
(NCT01617083 chunk 2): Antibiotic Treatment Trial for the PANDAS/PANS Phenotype. University of South Florida. 2012. ClinicalTrials.gov Identifier: NCT01617083
(wilbur2019pandaspansinchildhood pages 3-4): Colin Wilbur, Ari Bitnun, Sefi Kronenberg, Ronald M Laxer, Deborah M Levy, William J Logan, Michelle Shouldice, and E Ann Yeh. Pandas/pans in childhood: controversies and evidence. Paediatrics & child health, 24 2:85-91, Dec 2019. URL: https://doi.org/10.1093/pch/pxy145, doi:10.1093/pch/pxy145. This article has 117 citations and is from a peer-reviewed journal.
(NCT01617083 chunk 1): Antibiotic Treatment Trial for the PANDAS/PANS Phenotype. University of South Florida. 2012. ClinicalTrials.gov Identifier: NCT01617083
(wilbur2019pandaspansinchildhood pages 3-3): Colin Wilbur, Ari Bitnun, Sefi Kronenberg, Ronald M Laxer, Deborah M Levy, William J Logan, Michelle Shouldice, and E Ann Yeh. Pandas/pans in childhood: controversies and evidence. Paediatrics & child health, 24 2:85-91, Dec 2019. URL: https://doi.org/10.1093/pch/pxy145, doi:10.1093/pch/pxy145. This article has 117 citations and is from a peer-reviewed journal.